Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for Brian Fischer
-0.09 (-2.47%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.48 - 3.72
52 week 2.80 - 14.89
Open 3.65
Vol / Avg. 1.47M/1.54M
Mkt cap 382.90M
P/E     -
Div/yield     -
EPS -1.26
Shares 105.19M
Beta 4.06
Inst. own 82%
Feb 25, 2016
Q4 2015 Keryx Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 11, 2016
Keryx Biopharmaceuticals Inc at JPMorgan Healthcare Conference - Breakout Session - Webcast
Jan 11, 2016
Keryx Biopharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Dec 8, 2015
Keryx Biopharmaceuticals Inc at Oppenheimer Healthcare Conference
Nov 17, 2015
Keryx Biopharmaceuticals Inc at Stifel Healthcare Conference
Nov 10, 2015
Keryx Biopharmaceuticals Inc at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -730.63% -1030.19%
Operating margin -732.49% -1027.52%
EBITD margin - -1024.69%
Return on average assets -74.33% -135.67%
Return on average equity -91.96% -187.61%
Employees 155 -
CDP Score - -


750 Lexington Ave
NEW YORK, NY 10022-1200
United States - Map
+1-212-5315965 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxia's pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).

Officers and directors

Michael P. Tarnok Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Gregory Paul Madison Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Scott A. Holmes Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Brian R. Adams Vice President, General Counsel
Age: 41
Bio & Compensation  - Reuters
Abraham Ceesay Vice President of Marketing
Bio & Compensation  - Reuters
John F. Neylan Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Lauren Fischer Director
Bio & Compensation  - Reuters
John P Butler Independent Director
Age: 50
Bio & Compensation  - Reuters
Kevin J. Cameron Independent Director
Age: 46
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters